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Abstract-The direct effects of human GH and IGF-I on PRL secretion and cell proliferation 
were studied on PRL secreting rat pituitary tumor 73 156 cells in vitro, as well as the effects in 
vivo ofhuman GH administration on body weight, IGF-I levels and tumor sire in rats bearing this 
transplantable tumor. In the in vitro studies IGF-I levels above 5 nM stimulated PRL release in 
a dose-dependent manner while GH, in concentrations of 0.23-45 nM, did not affect PRL release. 
Cell proliferation toas stimulated by IGF-I in a dose-dependent manner from 0.5 nM onwards, 
while GH did not have an effect. The in vivo studies showed that 1 mg GH/rat/day prevented 
tumor-induced cachexia and normalized the suppressed IGF-I levels without stimulating tumor 
growth. It is concluded that tumor-induced cachexia can beprevented by exogenous GH administration 
without an increase in tumor mass, even if a tumor model is used whose cultured tumor cells respond 
to exposure to IGF-I with a mitotic response. 
INTRODUCTION 
IN ANIMALS, as well as in man, growth hormone 
(GH) exerts a wide variety of effects. Most of its 
growth-promoting actions are mediated via the 
formation of insulin-like growth factor I (IGF-I) 
while it also exerts a direct lipolytic action [l]. 
Knowledge about the effects and possible thera- 
peutic uses of GH in adults has been limited by the 
lack of available supplies. Therefore during the past 
decades its use has mainly been restricted to the 
treatment of children with short stature. 
After human GH, which is identical and bioequi- 
valent to endogenous GH, was produced by recom- 
binant DNA technology, new reports concerning 
the usefulness of GH therapy in adults with various 
catabolic disorders (trauma, surgery) were pub- 
lished [Z-5]. To date no studies have been carried 
out on the potential beneficial anabolic effects of 
GH therapy in cancer patients. 
Cancer-induced cachexia diminishes the quality 
of life significantly and may be attenuated by GH 
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therapy. The amount of weight loss in cancer pati- 
ents is positively correlated with the overall mor- 
tality. In addition, improvement of nutritional 
status may reduce chemotherapy related toxicity, 
as has recently been shown in a rat model [6]. The 
usefulness of (par)cnteral (hyper)alimentation in 
the management of cancer patients is controversial 
[7-lo]. 
Controversy exists also concerning the possible 
carcinogenic and/or tumor growth-stimulating 
effects of GH treatment in humans with GH 
deficiency, either direct or mediated by circulating 
or locally produced IGF-I [ 1 l-131. According to 
some investigators the incidence of neoplasms in 
acromegaly is increased [14-l 71, though others did 
not observe this relation [18, 191. 
In the present study we investigated the direct 
effects ofhuman GH and IGF-I on prolactin (PRL)- 
secreting rat pituitary tumor 7315b cells in vitro, as 
well as the effects of human GH administration to 
rats bearing the transplantable rat pituitary tumor 
731513. In the in vitro experiments the effects on 
cellular DNA content and PRL secretion were inves- 
tigated, while in the in uivo experiments changes in 
tumor size, body weight, plasma IGF-I, PRL and 
GH levels were studied. 
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MATERIALS AND METHODS 
In vitro tumor cell exfieriments 
Female Buffalo rats (R.B.I., Rijswijk, the 
Netherlands), weighing 150-170 g, were kept in an 
artificially illuminated room (08.30-20.30 h) with 
food and water ad libitum. The animals were inocu- 
lated subcutaneously between the scapulae with a 
cell suspension ofthe transplantable, PRL-secreting 
7315b rat pituitary tumor as described in detail 
elsewhere [20]. Three to four weeks after inoculation 
of the tumor cell suspension a tumor of approxi- 
mately 20 cm2 has grown on the back of the animals. 
At this moment the animals were killed by an 
overdose of ether anesthesia and the tumor was 
carefully removed and collected in a sterile saline 
solution (9 g/l NaCl) . 
731513 pituitary tumor cells were isolated by 
mechanical dispersion, The isolated tumor was 
washed twice with calcium-, magnesium-free 
Hank’s balanced salt solution (HBBS) sup- 
plemented with 1% human serum albumin (HSA), 
penicillin ( lo5 U/l), streptomycin (100 kg/l), fungi- 
zone (0.5 mg/l) and sodium bicarbonate (0.4 g/l 
final concentration). The capsula of the tumor was 
carefully removed, after which the tumor was 
minced into small pieces. The remaining suspension 
of tumor tissue was gently vortexed for 30 s. After 
vortexing the suspension was centrifuged at 600 g 
for 5 min and the pellet was washed twice with 
HBSS + HSA. The remaining pellet was resus- 
pended in HBSS + HSA and the suspension was 
filtered over a nylon gauze. In order to separate 
vital from non-vital cells the suspension was layered 
on Ficoll-Isopaque (density 1.077 g/ml; prepared 
by the Dijkzigt Hospital Pharmacy, Rotterdam, the 
Netherlands) and centrifuged at 500 g for 20 min. 
The interphase containing vital cells was collected 
and washed twice with HBSS + HSS. Finally, the 
cells were resuspended in culture medium. 
The culture medium used in all experiments 
consisted of minimal essential medium with Earle’s 
salts (MEM) supplemented with MEM non-essen- 
tial amino acids, sodium pyruvate ( 1 mmol/l), 10% 
fetal calf serum, penicillin (10” U/l), streptomycin 
(100 pg/l), f un izone g (0.5 mg/l), L-glutamine 
(2 mmol/l) and sodium bicarbonate (2.2 g/l final 
concentration). The medium was adjusted to pH 
7.4 with 1 mol/l NaOH. The 7315b pituitary tumor 
cells were seeded at a density of 20,000 cells per 
well in 1 ml of culture medium in 24-well plates 
(Costar, Cambridge, Mass, U.S.A.) without or with 
IGF-I or GH. The number of replicate points is 4. 
After 6 days of culture the media and cells were 
collected and stored at -20°C until analysis. 
Medium and supplements were purchased from 
Grand Island Biological Co. Europe (Paisley, 
U.K.). IGF-I was obtained from Bachem (Bachem 
Feinchemicalien ASG, Bubendorf, Switzerland) 
and human recombinant growth hormone (GH, 
Humatrope) from Eli Lilly & Co, Indianapolis. 
Rat PRL concentrations in the culture media 
were measured by a double antibody RIA using 
materials and protocols supplied by the distribution 
officer of the NIADDK. All results are expressed in 
rat prolactin reference preparation- 1 (RP- 1). 
The DNA content of the tumor cells was deter- 
mined as described in detail elsewhere [21]. The 
method is based on a DNA-dependent fluorescence 
enhancement of a fluorochrome. In short, cultured 
tumor cells, which did not attach to the floor of the 
wells, were collected at the end of the incubation 
period and washed twice with an ice-cold saline 
solution. The remaining cell pellet was stored at 
-20°C until analysis. The cells were extracted with 
300 ~1 ammonia solution (1 mol/l) + Triton Xl00 
(0.2% v/v) by sonification during 5 s at amplitude 
15 (Soniprep 150; MSE). Thereafter 2 ml assay 
buffer ( 100 mmol/l NaCI, 10 mmol/l EDTA, 10 
mmol/l Tris; pH 7.0) was added. The remaining 
solution was centrifuged at 2000 g during 5 min 
and 100 ~1 aliquots of the supernatant were mixed 
with 1.5 ml Hoechst dye H33258 (100 ng/ml). 
Fluorescence was measured after 15 min with the 
exication and emission wavelengths set at 350 nmol/ 
1 and 455 nmol/l respectively. Fluorescence ofexper- 
imental samples was referenced to a standard curve 
of calf thymus DNA (type II, no D-3636; Sigma 
Chemical Company, St Louis, MO, U.S.A.). 
Each experiment was done three times, the results 
shown relate to a single experiment. All data are 
expressed as mean * S.E. 
In vivo tumor experiments 
In two experiments the effect of GH adminis- 
tration on the growth of the 7315b tumor and on 
reversal (experiment 1) or prevention (experiment 
2) of tumor-induced cachexia was evaluated. Tumor 
growth was evaluated by expressing tumor size in 
centimeters squared (maximum length X maximum 
width) which has been shown to be closely corre- 
lated with tumor weight [22]. In the first experiment 
the effects of administration of 1 mg GH/rat/day 
(Humatrope, Eli Lilly & Co, Indianapolis) subcu- 
taneously in 0.25 ml diluent starting on day 13 after 
tumor implantation until the end of the experiment 
(day 23) were evaluated, while in the second exper- 
iment the effects of GH administration for 15 days 
starting on the day ofinoculation were evaluated. In 
both experiments tumor-bearing controls received 
daily injections of diluent only while in the second 
experiment the effects of either GH or diluent was 
evaluated in non-tumor-bearing controls as well. 
Each group of animals consisted of six rats. 
Plasma IGF-I levels were measured in EDTA 
plasma obtained from the tail vein during the exper- 
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iment or after decapitation at the end of the exper- 
iment. The commercial kit for the determination of 
IGF-I from the Nichol’s Institute of Diagnostics 
(San Juan Capistrano, CA, U.S.A.) was used. The 
intra-assay cv was 7.2 and the inter-assay cv 12.8%. 
PRL was determined in the same samples by double 
antibody RIA as described above. 
Statistical evaluation 
Statistical analysis was done by analysis of vari- 
ance, followed by Duncan’s test for determining 
the differences between control and experimental 
groups. In the in viuo experiments changes in body 
weight were evaluated by Student’s unpaired t test. 
RESULTS 
The effects of IGF-I and GH on PRL secretion and DNA 
content of cultured 73 156 tumor cells 
The 73 15b tumor cells were cultured for a period 
of 6 days. The effects of a wide concentration range 
of IGF-I (0.5-50 nmol/l) and GH (0.23-45 nmol/l) 
were investigated (Fig. 1). Low concentrations of 
0.5 and 1 nmol/l IGF-I did not affect PRL release, 
while 5, 10 and 50 nmol/l IGF-I stimulated PRL 
release in a dose-dependent manner (5 nmol/l vs. 
control: P < 0.01; 10 vs. 5 nmol/l: P < 0.05; 50 
vs. 10 nmol/l: P < 0.05). A low concentration of 
IGF-I (0.5 nmol/l) stimulated the DNA content of 
the cells after 6 days by 12% (P < 0.05 vs. control), 
while higher concentrations of IGF-I stimulated the 
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DNA content in a dose-dependent manner, 10 
nmol/l being the maximal stimulatory concentration 
(stimulation by 1, 5, 10 and 50 nmol/l IGF-I being 
24, 37, 50 and 55% respectively, 1 and 5 vs. 
0.5 nmol/l: P < 0.05; 10 and 50 vs. 1 nmol/l: 
P < 0.01). We also measured the IGF-I concen- 
tration of the culture medium used in these exper- 
iments: the final IGF-I concentration ofthe medium 
to which the control cells were exposed amounted 
to 0.2 nmol/l. 
Human GH in a concentration between 0.23 and 
45 nmol/l did not affect PRL release, while it did 
also not influence the DNA content of the tumor 
cells after 6 days of culture (Fig. 1). 
The effect of the administration of human GH in vivo on 
73 15b tumor growth, body and organ weights, serum PRL 
and IGF-I levels in rats 
The daily, subcutaneous administration of a 
pharmacological dose of 1 mg GH/rat per day for 
lo-15 days was investigated on 7315b tumor 
growth in two separate experiments. 
In the first experiment GH was injected daily 
from day 13 till 23 after tumor implantation. GH 
administration did not affect pituitary tumor 
growth: tumor size (as expressed in cm2) did not 
differ from that found in tumor-bearing animals 
which received the diluent only (Fig. 2). In contrast, 
however, the GH-treated tumor bearing rats had 
gained weight considerably. In Fig. 2 it is shown 
that tumor-bearing control animals gained 
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Fig. 1. The effects of increasing concentrations ofIGF-I (upperpanels) and GH (lower panels) on rat PRI, release (ng/6 days) 
and DNA content (nglwell) of 73 156 tumor cells culturedfor 6 days. 
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Fig. 2. The effects on body meight, uncorrected for tumor weight (left panel; g) and tumor size (right panel; cm’) of the 
administration of human GH (1 mg/ral/day) or placebo for 10 days to rats bearing the transplantable rat pituitary tumor 7315b 
starting on day 13 after tumor implantation. n = 6for each group; mean + S.E.M. 
4.5 t 6 g (mean 2 S.E.M.) in weight during the 
10 day placebo treatment period, while the GH 
treated tumor-bearing rats gained 24.3 + 1 g. 
5 
After deduction of the mean tumor weight 
(35.1 + 5 g in the placebo treated and 40.5 k B 
in the GH-treated animals; NS) the weight of the 
placebo-treated animals amounted to 166 t 6 g, 
indicating a mean body weight gain of only 3 k 2 g, 
in comparison with the mean body weight prior to 
tumor implantation. The actual mean body weight 
ofthe GH-treated group at the end ofthe experiment 
amounted to 180 rt 4g (220.5 t 5.4 minus 
40.5 k 2). Therefore the GH-treated animals had 
gained 18 + 2 g in weight during the 22 day inves- 
tigational period. This weight gain did not differ 
from that observed in non-tumor-bearing controls 
(starting weight 161 + 2.8, final weight 
175.3 k 3.7) but was higher than that seen in the 
tumor-bearing control rats (P < 0.01). In compari- 
son with non-tumor-bearing controls plasma IGF-I 
levels were slightly lowered on day 12 after tumor 
implantation (NS, Table la). This decrease was 
statistically significant in the tumor-bearing con- 
trols 18 and 22 days after tumor implantation 
(P < 0.05), while GH treatment in tumor-bearing 
animals resulted in a significant stimulation of 
IGF-I to levels which were comparable with those 
observed in non-tumor-bearing controls (both on 
day 18 and 22: P < 0.05 vs. tumor-bearing 
controls). 
Prolactin levels in the GH treated tumor-bearing 
group did not differ significantly from the placebo- 
treated tumor-bearing animals (1133 2 156 vs. 
771 + 163 ng/ml), though both were significantly 
higher compared with the non-tumor-bearing con- 
trols (81 k 32). 
In the second experiment GH administration 
was started on the day of tumor implantation and 
continued for 15 days. Again no significant effect of 
GH administration on tumor growth was observed 
(Fig. 3). GH exerted powerful stimulatory effects on 
body growth both in the non-tumor- and in the 
tumor-bearing animals. The placebo-treated non- 
tumor-bearing rats gained 14 t 2 gin weight, while 
in the GH-treated control group this amounted to 
33 + 3 g (P < 0.01). The tumor-bearing placebo- 
treated rats gained 34 + 4 g in weight, but after 
deduction of tumor weight (26 2 4 g) net weight 
gain was only 8 k 2 g. Growth hormone adminis- 
tration to tumor-bearing animals resulted in a total 
weight gain of 49 2 4 g; after deduction of tumor 
weight (29 k 7): 20 -+ 2 g (P < 0.01 vs. tumor- 
bearing placebo-treated rats). 
After 15 days of GH treatment plasma IGF-I 
levels in the GH treated non-tumor-bearing rats 
were significantly elevated compared with the plac- 
ebo-treated non-tumor-bearing animals (P < 0.05; 
Table 1 b). The consequences of tumor implantation 
on IGF-I levels again became evident: both on day 
16 and 22 they were significantly suppressed in 
comparison with the placebo-treated non-tumor- 
bearing rats (P < 0.05 in both instances). Adminis- 
tration ofGH to tumor-bearing rats resulted already 
on day 9 but also on day 16 in a stimulation of 
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Table la. The effect of GH (1 mg/rat/day) or placebo administration on the total plasma 
IGF-I concentration (nmolh) of rats with the pituitary tumor 73 156, for 10 days starting on 
day 12 after tumor implantation (mean + S.E.M.; n = 6 per group) 
Day 12 
IGF-I (nmol/l) 
18 22 
Control non-tumor 25.3 k 1.6 23.6 f 1.0 27.2 t 2.4 
Control tumor 23.1 t 1.7 17.2 rt 1.1* 19.7 c 0.9* 
Tumor + GH 23.2 t 0.8 27.7 2 1.7t 28.5 t 0.71 
*P Cc 0.05 vs. control non-tumor. 
+P i 0.05 vs. control tumor. 
Table lb. The effect of GH (1 mg/rat/day) or placebo administration on the total plasma IGF-I concentration 
(nmol/l) of rats with the pituitav tumor 73156, for 15 days starting on the day of tumor implantation (mean 2 
S.E.M.; n = 6 per group) 
IGF-I (nmolh) 
Day 9 16 22 
Non-tumor placebo 20.6 k 1.0 22.2 k 0.5 21.4 2 1.0 
Non-tumor + GH 23.9 2 1.1 28.1 + 0.6* 25.0 t 1.0’ 
Tumor placebo 18.3 k 0.7 16.9 2 0.5* 14.1 + 1.1* 
Tumor + GH 23.8 t 1.17 25.9 f 0.7t 15.8 t 1.1 
*P < 0.05 vs. non-tumor placebo 
tP < 0.05 vs. tumor placebo. 
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Fig. 3. The effects on body weight, uncorrected for tumor weight (left panei; g) and tumor size (right panel; cm’) of the 
administration of human GH (1 mg/rat/day) or placebo for 15 days to rats with or without the transplantable rat pituitary tumor 
73156 implanted on day 1. n = 6for each group; mean r+ S.E.M. On day 22 body weights correctedfor tumor weight were 
166 2 5 in the control tumor and 178 + 5 in the HCH treated tumor group. 
IGF-I levels, which were significantly higher than 
in the placebo-treated tumor-bearing animals 
(P < 0.05). These levels were, both on day 9 and 
16, similar to those observed in GH treated non- 
tumor-bearing rats, and on day 16 also higher 
than in placebo treated non-tumor-bearing controls 
(P < 0.05). On day 22 the stimulatory effects of 
GH administration in the first 15 day period had 
ceased and IGF-I levels had indeed decreased to 
levels comparable with those in the placebo-treated 
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tumor-bearing group. PRL levels in the GH-treated 
tumor-bearing group again did not differ signifi- 
cantly from the placebo-treated tumor-bearing rats 
(618 + 195 vs 520 4 103 ng/ml). PRL levels were 
elevated in both tumor-bearing groups compared 
with both non-tumor-bearing groups (PRL level 
35 + 6 in the non-tumor placebo-treated and 
26 * 7 ng/ml in the non-tumor GH-treated rats). 
DISCUSSION 
Evidence is accumulating that IGF-I plays a 
role in tumorigenesis and tumor growth. In vitro 
investigation of several tumor cell lines demonstrate 
specific binding sites for IGF-I [23-311, increased 
binding to IGF-I receptors when compared with 
less dedifferentiated cell lines or with normal sur- 
rounding tissue [24, 29-311, production of IGF-I 
by tumor cell lines or tissue [32, 331 and increased 
DNA synthesis and cell growth in response to IGF- 
I [23, 25, 27-29, 32, 34-361. 
From these observations one might derive strong 
arguments against the therapeutic use of GH to 
reduce catabolism and/or induce an anabolic state 
in patients with cancer-induced cachexia, since it 
might simultaneously stimulategrowth ofthe cancer 
itself. In addition evidence was also presented from 
studies by Friesen’s group that GH directly induces 
the expression of the c-myc oncogene in rat liver 
[371. 
Preliminary results (J. Foekens, personal 
communication) from investigations into the pres- 
ence of IGF-I binding sites on the rat pituitary 
tumor cell line 7315b used in this study indicate 
indeed the presence of specific high affinity IGF-I 
binding sites on this tumor. 
The results of the in vitro studies are in accordance 
with similar studies in other cancer cell lines, in that 
it was shown that IGF-I induced cell proliferation 
and protein (in this case PRL) secretion. GH itself 
did not induce either effect. 
The results of the in vivo studies show that GH 
administration for 10-15 days prevents tumor- 
induced cachexia without stimulating tumor growth 
measured in cm2 or PRL secretion. On a weight 
basis we used 120-240 times the GH dosage used 
in human studies to induce an anabolic state [38]. 
The discrepancy between the (mitogenic) effect 
of IGF-I in vitro and the absence ofeffects ofelevated 
IGF-I levels on tumor growth in vivo might be 
explained by the possibility with the low IGF-I 
levels in cachectic animals are sufficient to optimize 
tumor growth, since the lowest IGF-I level meas- 
ured in vivo is 14 nM, while levels of 10 and 50 nM 
in the in vitro experiments stimulated cell prolifer- 
ation to a similar extent. An auto- or paracrine effect 
of IGF-I generated by the tumor cells themselves 
cannot be excluded but seems unlikely since we 
found virtually no IGF-I production by these cells 
in vitro IGF-I (concentration in the control culture 
medium after 6 days 0.2 nM). 
Our results are in disagreement with the results 
of Svaninger et al. [39], who demonstrated no 
improvement ofbody composition and muscle wast- 
ing (nor an increase in tumor growth) by GH 
administration in adult, non-growing, sarcoma- 
bearing mice, while in hypophysectomized rats GH 
administration stimulated body and tumor growth 
to a similar extent. In their sarcoma tumor model 
in intact animals GH levels were elevated from 
day 8 after tumor implantation, explained by the 
authors as a way to promote endogeneous substrate 
mobilization. The exogeneous GH dosage was only 
100 pg/lOO g body weight day (as opposed to our 
GH dose of 1 mg/rat, which corresponds to 600 pg/ 
100 g body weight/day) which was insufficient to 
stimulate growth in freely fed control mice. In their 
study no IGF-I levels were reported. 
In our study the decrease of IGF-I levels in tumor- 
bearing rats reflects the tumor induced cachexia 
[40. 411 and was reversible by GH administration. 
IGF-I levels decreased to the low level observed 
in untreated tumor-bearing rats within days after 
cessation of GH administration. 
In conclusion, tumor-induced cachexia in this 
rat model can be prevented by exogenous GH 
administration without an increase in tumor mass, 
even though this tumor model contains specific 
binding sites for IGF-I and the cultured tumor 
cells respond to exposure to IGF-I with a mitotic 
response. 
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